ACRX Gains On Coming Catalyst As mentioned abov
Post# of 74
(Total Views: 742)
Posted On: 07/17/2017 3:34:36 PM
ACRX Gains On Coming Catalyst
As mentioned above, AcelRx is having an incredibly strong day in the market today, and for good reason. A report pointed out that the company is undervalued and has a massive catalyst on the horizons.
On the valuation side of the equation, the argument is a very simple one. While the company has an average price of under $3 per share, they have assets worth far more than that. In fact, the company actually has $1.59 per share in cash alone.
Perhaps most importantly, there are two big catalysts coming surrounding the stock. First and foremost, the company has a treatment known as Dsuvia that is pending approval by the FDA. The PDUFA date for this potential approval comes in October. On top of that, there's Phase 3 data that will soon be released surrounding Zalviso. That data is expected to be released by the end of July. The value of these treatments, if they make it to the market, is incredibly high. In fact, it is estimated that ACRX could reach peak revenue from these treatments in the amount of $1.7 billion annually if all goes well.
As mentioned above, AcelRx is having an incredibly strong day in the market today, and for good reason. A report pointed out that the company is undervalued and has a massive catalyst on the horizons.
On the valuation side of the equation, the argument is a very simple one. While the company has an average price of under $3 per share, they have assets worth far more than that. In fact, the company actually has $1.59 per share in cash alone.
Perhaps most importantly, there are two big catalysts coming surrounding the stock. First and foremost, the company has a treatment known as Dsuvia that is pending approval by the FDA. The PDUFA date for this potential approval comes in October. On top of that, there's Phase 3 data that will soon be released surrounding Zalviso. That data is expected to be released by the end of July. The value of these treatments, if they make it to the market, is incredibly high. In fact, it is estimated that ACRX could reach peak revenue from these treatments in the amount of $1.7 billion annually if all goes well.
(0)
(0)Talphera Inc. (TLPH) Stock Research Links
Scroll down for more posts ▼